Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight
The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies are expanding treatment options and significantly boosting market demand. Additionally, the launch of emerging therapies such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others will further propel the market growth.
LAS VEGAS, March 5, 2026 /PRNewswire/ -- Recently published Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Chronic Rhinosinusitis with Nasal Polyps Market Summary
- The total chronic rhinosinusitis with nasal polyps treatment market size is expected to grow positively by 2036 in the leading markets.
- The United States accounted for the largest CRSwNP treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
- The 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period.
- Leading CRSwNP companies, such as Upstream Bio, GlaxoSmithKline, Sanofi, Eli Lilly, and others, are developing new CRSwNP treatment drugs that can be available in the CRSwNP market in the coming years.
- The promising CRSwNP therapies in clinical trials include Verekitug (UPB-101), Depemokimab (GSK3511294), Lunsekimig, LY3650150, and others.
Discover what is the forecast for the global CRSwNP market @ https://www.delveinsight.com/sample-request/chronic-rhinosinusitis-with-nasal-polyps-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the Chronic Rhinosinusitis with Nasal Polyps Market
- Rising CRSwNP Disease Burden: CRSwNP is expected to see a rising disease burden over the forecast period (2026–2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches.
- Impact of Nucala and Xolair Approvals on CRSwNP Treatment: The coveted approvals of NUCALA and XOLAIR in the overall existing treatment have added effectiveness in treating CRSwNP.
- Launch of Emerging CRSwNP Therapies: The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients.
Chronic Rhinosinusitis with Nasal Polyps Market Analysis
- The current treatment of CRSwNP includes corticosteroids (intranasal and systemic) in addition to anti-histamines, antibiotics, and NSAIDs, which are given depending on the patient's need.
- When drug treatment doesn't shrink or eliminate nasal polyps, endoscopic surgery is recommended to remove polyps and correct sinus problems that lead to inflammation and polyp development.
- After surgery, a corticosteroid nasal spray is recommended to prevent recurrence of nasal polyps along with biologics.
- Over the years, the US FDA has approved multiple corticosteroids and biologics for CRSwNP, including XHANCE (fluticasone propionate), SINUVA (mometasone furoate) sinus implant, PROPEL (mometasone furoate), DUPIXENT (dupilumab), XOLAIR (omalizumab), and NUCALA (mepolizumab).
- In February 2026, GSK reported that the European Commission approved EXDENSUR (depemokimab) as an add-on therapy with intranasal corticosteroids for adults with severe CRSwNP not adequately controlled with systemic corticosteroids and/or surgery.
- The approval of EXDENSUR was supported by Phase III SWIFT and ANCHOR trial data showing statistically significant and clinically meaningful improvements compared with standard of care alone.
- With this decision, EXDENSUR became the first and only ultra-long-acting biologic approved in the European Union for respiratory diseases, including severe CRSwNP.
- Several companies are actively working in the CRSwNP market. The launch of emerging drugs such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others will change the market dynamics.
Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape
CRSwNP pipeline possesses some drugs in late stage developments to be approved in the near future. Expected launch of emerging therapies, such as Depemokimab (GlaxoSmithKline), Verekitug (UPB-101) (Upstream Bio), Lunsekimig (Sanofi), LY3650150 (Eli Lilly), and others, are expected to further create a positive impact on the market.
Upstream Bio's Verekitug is an engineered, fully human IgG1 monoclonal antibody that targets the TSLP receptor, blocking TSLP-driven pro-inflammatory signaling. In preclinical testing, it showed strong receptor occupancy and robust inhibition of TSLP pathways. Verekitug also reduced cytokine release from CD4+ T cells and ILC2s and completely prevented allergic skin responses in a non-human primate model, indicating potential effectiveness across multiple inflammatory conditions.
GSK is developing depemokimab as a treatment for CRSwNP. This humanized monoclonal antibody against interleukin-5 (IL-5) is designed to bind IL-5 with high affinity and provide long-lasting suppression of IL-5–dependent activity, supporting extended control of eosinophil-driven inflammation.
The anticipated launch of these emerging therapies are poised to transform the CRSwNP market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the CRSwNP market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about emerging drugs for chronic sinusitis with nasal polyps @ Chronic Rhinosinusitis with Nasal Polyps Drugs
Recent Developments in the Chronic Rhinosinusitis with Nasal Polyps Market
- In February 2026, GSK announced that the European Commission had authorized EXDENSUR (depemokimab) as an add-on treatment alongside intranasal corticosteroids for adults with severe CRSwNP who remain insufficiently controlled despite systemic corticosteroids and/or surgery.
- In January 2026, GSK reported that Japan's Ministry of Health, Labour and Welfare approved EXDENSUR (depemokimab) for the treatment of CRSwNP in patients inadequately controlled with standard therapy.
- In December 2025, the US FDA approved depemokimab for severe asthma but did not approve the CRSwNP indication, without providing detailed reasons. GSK has expressed continued confidence in the therapy's potential for CRSwNP and is maintaining discussions with the FDA.
- In October 2025, TEZSPIRE was approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with inadequately controlled CRSwNP, making it the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.
- In September 2025, Upstream Bio reported positive top-line results from the Phase II VIBRANT trial evaluating verekitug for the treatment of CRSwNP. In the 24-week study, verekitug administered at 100 mg every 12 weeks met its primary endpoint, demonstrating a statistically significant and clinically meaningful placebo-adjusted reduction in endoscopic nasal polyp score (NPS) of –1.8.
What is Chronic Rhinosinusitis with Nasal Polyps?
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a long-lasting inflammatory condition of the nose and sinuses in which soft, painless, noncancerous growths, called nasal polyps, develop inside the nasal passages or sinus cavities. These polyps form when the lining of the nose becomes persistently swollen and irritated, often due to immune system dysfunction. People with CRSwNP commonly experience symptoms such as nasal blockage, reduced or lost sense of smell, facial pressure, congestion, and recurring sinus infections. Because the inflammation is ongoing and the polyps tend to recur even after treatment, CRSwNP is considered a chronic condition that often requires long-term medical management.
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation
The CRSwNP epidemiology section provides insights into the historical and current CRSwNP patient pool and forecasted trends for the leading markets. The US had the highest diagnosed prevalent cases of CRSwNP in the 7MM, with around 2 million cases in 2025. The gender distribution of the disease suggests a male predominance in the US, with 55% of the diagnosed prevalent cases of CRSwNP being males.
The CRSwNP treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
- Prevalent Cases of CRS
- Diagnosed Prevalent Cases of CRS
- Diagnosed Prevalent Cases of CRSwNP
- Gender-specific Diagnosed Prevalent Cases of CRSwNP
- Total Treated Cases of CRSwNP
Chronic Rhinosinusitis with Nasal Polyps Market Report Metrics | Details |
Study Period | 2022–2036 |
Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. |
Chronic Rhinosinusitis with Nasal Polyps Epidemiology Segmentation | Prevalent Cases of CRS, Diagnosed Prevalent Cases of CRS, Diagnosed Prevalent Cases of CRSwNP, Gender-specific Diagnosed Prevalent Cases of CRSwNP, and Total Treated Cases of CRSwNP |
Key Chronic Rhinosinusitis with Nasal Polyps Companies | Upstream Bio, GlaxoSmithKline, Sanofi, Eli Lilly, AstraZeneca, Amgen, Regeneron Pharmaceuticals, and others |
Key Chronic Rhinosinusitis with Nasal Polyps Therapies | Verekitug (UPB-101), Depemokimab (GSK3511294), Lunsekimig, LY3650150, NUCALA, TEZSPIRE, DUPIXENT, and others |
Scope of the Chronic Rhinosinusitis with Nasal Polyps Market Report
- Therapeutic Assessment: Chronic Rhinosinusitis with Nasal Polyps current marketed and emerging therapies
- Chronic Rhinosinusitis with Nasal Polyps Market Dynamics: Key Market Forecast Assumptions of Emerging Chronic Rhinosinusitis with Nasal Polyps Drugs and Market Outlook
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Chronic Rhinosinusitis with Nasal Polyps Market Access and Reimbursement
Download the report to understand CRSwNP market CAGR projections @ Chronic Rhinosinusitis with Nasal Polyps Market Analysis
Table of Contents
1 | Chronic Rhinosinusitis with Nasal Polyps Market Key Insights |
2 | Chronic Rhinosinusitis with Nasal Polyps Market Report Introduction |
3 | Nasal Polyps Market Overview at a Glance |
3.1. | Market Share (%) Distribution of CRSwNP by Therapies in 2025 |
3.2. | Market Share (%) Distribution of CRSwNP by Therapies in 2036 |
4 | Epidemiology and Market Forecast Methodology |
5 | Executive Summary |
6 | Key Events |
7 | Disease Background and Overview |
7.1. | Introduction |
7.2. | Signs and Symptoms |
7.3. | Etiology |
7.4. | Causes |
7.5. | Pathogenesis |
7.6. | Diagnostic Approach |
7.7. | Treatment and Management |
8 | Epidemiology and Patient Population |
8.1. | Key Findings |
8.2. | Methodology of Epidemiology |
8.3. | Assumptions and Rationale: the 7MM |
8.3.1. | The US |
8.3.2. | EU4 and the UK |
8.3.3. | Japan |
8.4. | Total Diagnosed Prevalent Cases of CRSwNP in the 7MM |
8.5. | The United States |
8.5.1. | Prevalent Cases of CRS in the US |
8.5.2. | Diagnosed Prevalent Cases of CRS in the US |
8.5.3. | Diagnosed Prevalent Cases of CRSwNP in the US |
8.5.4. | Gender-specific Diagnosed Prevalent Cases of CRSwNP in the US |
8.5.5. | Total Treated Cases of CRSwNP in the US |
8.6. | EU4 and the UK |
8.7. | Japan |
9 | CRSwNP Patient Journey |
10 | Marketed CRSwNP Therapies |
10.1. | Key Cross Competition |
10.2. | NUCALA (mepolizumab): GlaxoSmithKline |
10.2.1. | Product Description |
10.2.2. | Regulatory Milestones |
10.2.3. | Other Developmental Activities |
10.2.4. | Clinical Trials Information |
10.2.5. | Safety and Efficacy |
10.2.6. | Analyst Views |
10.3. | TEZSPIRE (tezepelumab): AstraZeneca/Amgen |
10.4. | DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals |
List to be continued in the final report | |
11 | Emerging CRSwNP Drugs |
11.1. | Key Cross Competition |
11.2. | Verekitug (UPB-101): Upstream Bio |
11.2.1. | Product Description |
11.2.2. | Other Developmental Activities |
11.2.3. | Clinical Development |
11.2.4. | Clinical Trials Information |
11.2.5. | Safety and Efficacy |
11.2.6. | Analyst Views |
11.3. | Depemokimab (GSK3511294): GlaxoSmithKline |
List to be continued in the final report | |
12 | CRSwNP: Market Analysis |
12.1. | Key Findings |
12.2. | Key CRSwNP Market Forecast Assumptions |
12.3. | CRSwNP Market Outlook |
12.4. | Attribute Analysis |
12.5 | Total Market Size of CRSwNP in the 7MM |
12.6 | Market Size of CRSwNP by Therapies in the 7MM |
12.7 | Market Size of CRSwNP in the US |
12.7.1. | Total Market Size of CRSwNP in the US |
12.7.2. | Market Size of CRSwNP by Therapies in the US |
12.8 | Market Size of CRSwNP in EU4 and the UK |
12.9 | Market Size of CRSwNP in Japan |
13 | KOL Views on CRSwNP |
13.1. | The United States |
13.2. | The EU4 and the UK |
13.3. | Japan |
14 | CRSwNP Market SWOT Analysis |
15 | CRSwNP Market Unmet Needs |
16 | Reimbursement and Market Access |
16.1 | The US |
16.2 | In EU4 and the UK |
16.3 | Japan |
17. | Bibliography |
18 | Abbreviations and Acronyms |
19 | CRSwNP Market Report Methodology |
Related Reports
Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Analysis
Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CRSwNP companies, including Keymed Biosciences Co., Ltd., GlaxoSmithKline, Genrix (Shanghai) Biopharmaceutical Co., Ltd., Guangdong Hengrui Pharmaceutical Co., Ltd, and others.
Chronic Rhinosinusitis without Nasal Polyps Market
Chronic Rhinosinusitis without Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRSsNP companies including Optinose US Inc., Lyra Therapeutics, Insmed, Inc., Sanofi, Regeneron Pharmaceuticals, and others.
Chronic Rhinosinusitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic rhinosinusitis companies including Connect Biopharma, Lyra Therapeutics, Sanotize Research and Development Corp., Regeneron Pharmaceuticals, AstraZeneca, Kyowa Kirin Co., Ltd., Keymed Biosciences Co.Ltd, Pfizer, GlycoMira Therapeutics, and others.
Nasal Polyps Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key nasal polyps companies including Sanofi, Regeneron, GSK, Optinose, AstraZeneca, Novartis, Intersect ENT Inc., Teva Pharmaceutical Industries, Merck & Co., Cipla Ltd., Dr. Reddy's Laboratories, Genentech (Roche), Sun Pharmaceutical Industries, Lyra Therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Share this article